Hashimoto’s disease can cause anemia, and it does so more often than many patients or even their doctors expect. Studies of people with hypothyroidism, which Hashimoto’s is the leading cause of, consistently find anemia in roughly 40 to 67 percent of patients, depending on the population studied and how anemia is defined. The connection runs through several biological pathways, from the direct role thyroid hormones play in red blood cell production to iron absorption problems, heavy menstrual bleeding, and the tendency of autoimmune diseases to travel in packs.
How Common Is Anemia in People With Hypothyroidism
The numbers vary across studies, but anemia shows up far more often in hypothyroid patients than in the general population. A cross-sectional study of 413 hypothyroid patients found anemia in 40 percent of them.1PubMed Central. Frequency and characteristics of anemia in hypothyroid patients: A cross-sectional study A prospective study of 176 patients with primary hypothyroidism put the figure even higher, at 67 percent.2PubMed Central. Frequency and Types of Anemia in Primary Hypothyroidism Patients: A Prospective Observational Study A nationally representative U.S. analysis using two decades of survey data found a lower overall prevalence of about 12 percent among all thyroid disease patients, with that figure rising over time from roughly 10 percent in the earlier decade to nearly 14 percent in the later one.3Endocrine and Metabolic Science. Prevalence and temporal trends of anemia in patients with thyroid disease: 1999–2018 NHANES
The wide range makes sense when you consider that clinical studies typically recruit patients already coming in for treatment, many of whom have more advanced thyroid dysfunction, while national surveys capture milder and even subclinical cases. The takeaway is the same regardless of which number you land on: if you have Hashimoto’s or hypothyroidism, your chances of being anemic are meaningfully elevated, and the anemia can sometimes appear before the thyroid diagnosis itself does.
How Thyroid Hormones Drive Red Blood Cell Production
Your bone marrow is where red blood cells are made, and thyroid hormones have a direct hand in that process. Research in animal models has shown that the thyroid hormones T3 and T4 stimulate the growth of red blood cell precursors in the bone marrow, and that this effect is independent of erythropoietin, the kidney-produced hormone most people associate with red blood cell production.4PubMed. Direct effects of thyroid hormones on bone marrow erythroid cells of rats In other words, thyroid hormones don’t just nudge the kidneys to signal for more red blood cells; they also act directly on the bone marrow itself.
Studies in mice have further demonstrated that T3 accelerates the maturation of early red blood cell progenitors into fully functional erythrocytes.5PLOS Genetics. Defective erythropoiesis caused by mutations of the thyroid hormone receptor α gene When Hashimoto’s destroys enough thyroid tissue to reduce hormone output, the bone marrow loses one of its key accelerators. The result is a sluggish production line: fewer red blood cells made per unit of time, and potentially smaller or less hemoglobin-loaded cells making it out the door. This mechanism explains why even patients without any iron or vitamin deficiency can still become anemic once hypothyroidism sets in.
Not Just One Kind of Anemia
One of the things that makes anemia in Hashimoto’s patients tricky is that it doesn’t come in a single flavor. When researchers look at the blood under a microscope, they find at least three distinct patterns, each pointing to a different underlying problem:
- Normocytic anemia: Red blood cells are a normal size but there just aren’t enough of them. This is the most common type in hypothyroid patients, showing up in roughly 39 to 45 percent of anemic cases across studies. It reflects the bone marrow slowdown described above.2PubMed Central. Frequency and Types of Anemia in Primary Hypothyroidism Patients: A Prospective Observational Study
- Microcytic anemia: Red blood cells are smaller than normal and carry less hemoglobin, the hallmark of iron deficiency. About 19 to 35 percent of anemic hypothyroid patients fall into this category.6European Journal of Cardiovascular Medicine. Assessment of Anaemia in Patients with Hypothyroidism: Clinical and Hematological Correlation
- Macrocytic anemia: Red blood cells are abnormally large, suggesting a deficiency in vitamin B12 or folate. This occurs in about 9 to 21 percent of anemic cases.
The fact that normocytic anemia dominates is a clue that the thyroid’s effect on the bone marrow is the primary driver for many patients, not simply a vitamin or mineral shortfall. But the frequent appearance of microcytic and macrocytic forms tells you that nutrient deficiencies pile on top of the hormonal problem in a substantial minority of people.
Multiple Roads to Iron Deficiency
Iron deficiency is the world’s most common nutritional deficiency, and Hashimoto’s patients face several compounding factors that make it even more likely. One is impaired iron absorption. Hypothyroidism appears to reduce the gut’s ability to absorb iron effectively, possibly by lowering gastric acid production or altering the intestinal lining’s transport mechanisms.7The American Journal of Medicine. Treatment of Iron-deficiency Anemia in Patients with Subclinical Hypothyroidism You can eat enough iron-rich food and still not absorb it well when your thyroid hormone levels are low.
Another pathway involves a protein called hepcidin, which acts as the body’s iron gatekeeper. When hepcidin levels rise, iron gets locked away inside cells and can’t enter the bloodstream where it’s needed for hemoglobin production. Research has found that hepcidin levels are elevated in hypothyroid patients with Hashimoto’s and drop once thyroid hormone levels are brought back to normal with treatment.8PubMed Central. The hepcidin concentration decreases in hypothyroid patients with Hashimoto’s thyroiditis following restoration of euthyroidism This means the thyroid dysfunction itself may be locking up iron stores, creating a functional deficiency even when total body iron isn’t critically low.
For premenopausal women, heavy menstrual bleeding adds a third route. Hypothyroidism disrupts the normal hormonal regulation of menstrual cycles and can cause prolonged or unusually heavy periods. In severe cases the blood loss can be dramatic. A published case described a 13-year-old girl who presented to an emergency department with menorrhagia lasting 15 days, which caused severe anemia. Workup revealed she had severe hypothyroidism from autoimmune thyroiditis along with an acquired bleeding disorder.9PubMed Central. Menorrhagia as main presentation sign of severe hypothyroidism in a pediatric patient: a case report While that’s an extreme example, milder versions of the same pattern are common. Heavier-than-normal periods draining iron stores month after month can quietly push someone into iron-deficiency anemia, and the menstrual changes may be dismissed as normal variation rather than investigated as a thyroid-related symptom.
Shared Genetic and Autoimmune Roots
Hashimoto’s is an autoimmune disease, and autoimmune diseases have a well-known tendency to cluster. If you have one, you’re at increased risk for others. A large multi-ancestry genome-wide association study of Hashimoto’s thyroiditis found that many of the genetic variants linked to Hashimoto’s also show associations with anemia when researchers tested those variants against a wide range of health conditions.10Nature Genetics. Multi-ancestry genome-wide association analyses provide insights into the genetic basis of Hashimoto’s thyroiditis This hints that some of the anemia risk in Hashimoto’s patients isn’t just a downstream consequence of low thyroid hormone, but may share a common genetic predisposition.
One clinically relevant example is autoimmune gastritis, a condition in which the immune system attacks the acid-producing cells of the stomach. Research on Hashimoto’s patients has found that those who test positive for anti-parietal cell antibodies, a marker of autoimmune gastritis, tend to be older and have a higher rate of other organ-specific autoimmune diseases compared to antibody-negative Hashimoto’s patients.11PubMed Central. Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies Autoimmune gastritis matters for anemia because it destroys the cells that produce intrinsic factor, a protein needed to absorb vitamin B12. Without adequate B12, the body makes oversized, dysfunctional red blood cells, leading to macrocytic anemia. It also reduces stomach acid, which impairs iron absorption. So the same autoimmune tendency that produced Hashimoto’s can independently create conditions ripe for anemia through a completely separate organ.
Celiac disease is another autoimmune condition that frequently coexists with Hashimoto’s. It damages the lining of the small intestine, precisely where iron and folate are absorbed. Patients who have both conditions face a double hit to their ability to maintain healthy red blood cells, one from the thyroid dysfunction and another from impaired nutrient absorption in the gut.
Does Vitamin B12 or Folate Deficiency Explain the Macrocytic Cases
The short answer is: sometimes, but not as reliably as you might expect. Some clinicians routinely screen Hashimoto’s patients for B12 and folate deficiency, assuming that autoimmune thyroid disease drives these down. The evidence is more mixed than the clinical habit suggests. One study looking at folic acid and B12 across the spectrum of thyroid function found that while folic acid levels tracked with thyroid stimulating hormone levels, the actual prevalence of outright B12 or folate deficiency didn’t differ significantly between hypothyroid and euthyroid groups.12PubMed. Prevalence of folic Acid and vitamin B12 deficiencies in patients with thyroid disorders That study’s authors concluded that routine screening for these deficiencies in subclinical thyroid dysfunction isn’t strongly supported, though it may still be warranted in overt hypothyroidism.
A separate clinical study comparing Hashimoto’s patients directly with healthy controls found no statistically significant difference in hemoglobin, ferritin, B12, or folic acid levels between the groups.13Journal of Health Sciences and Medicine. Evaluation and epigenetic impact of B12, vitamin D, folic acid and anemia in Hashimoto’s thyroiditis: a clinical and molecular docking study This doesn’t mean Hashimoto’s patients never develop B12 or folate deficiency. It means the thyroid disease alone isn’t a consistent enough driver to rely on blanket screening. The patients most at risk for these specific deficiencies are those with co-occurring autoimmune gastritis or celiac disease, where the absorption problem has a clear anatomical basis.
Why Treating Both Conditions Together Matters
One of the most practical findings for patients is that treating the anemia and the hypothyroidism simultaneously produces dramatically better results than treating either one alone. A randomized controlled trial of subclinical hypothyroid patients with iron deficiency compared three groups: iron supplementation alone, levothyroxine alone, and combined iron plus levothyroxine. The combined group saw their hemoglobin rise by an average of 1.9 g/dL, while the iron-only group gained just 0.4 g/dL. Improvements in serum iron, ferritin, and red blood cell count were all significantly greater in the combined treatment group.14PubMed. Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: a randomized, double-blind, controlled study
This is a finding worth internalizing. If you’ve been told you’re anemic and handed an iron supplement without anyone checking your thyroid, the iron may barely move the needle. The reverse also holds: starting levothyroxine without addressing a concurrent iron deficiency may leave you still feeling exhausted, foggy, and short of breath because the anemia hasn’t been corrected. The two conditions feed each other, and breaking the cycle requires treating both.
Some clinicians have described anemia as the “haematological mask” of hypothyroidism because it can appear first and dominate the clinical picture, sending doctors down a hematology rabbit hole while the underlying thyroid problem goes unrecognized. Patients with unexplained anemia that doesn’t respond normally to iron or B12 supplementation should ask whether their thyroid function has been tested, and patients with new Hashimoto’s diagnoses should have a complete blood count run if one hasn’t been done recently.15Konuralp Medical Journal. Investigation of Hemoglobin, Iron, Ferritin, and Vitamin B12 Levels in Patients with Primary Hypothyroidism
The Iron Supplement and Levothyroxine Timing Trap
Here is where the treatment picture gets complicated in a way that catches many patients off guard. Iron supplements and levothyroxine bind to each other in the gut, forming a poorly absorbed complex that reduces the effectiveness of both. In one early study, patients taking ferrous sulfate alongside their levothyroxine saw their TSH levels climb from a well-controlled average of 1.6 to 5.4 mU/L over 12 weeks, with nine out of fourteen patients developing clinical symptoms of worsening hypothyroidism.16PubMed. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism When the researchers mixed iron and thyroxine in a test tube, they could actually see a purple precipitate forming, a visible chemical complex that neither the body nor the gut can use efficiently.
The standard advice is to separate iron supplements from levothyroxine by at least four hours. But even that gap may not fully prevent the interaction in some patients. Case reports describe hypothyroidism worsening despite patients following the recommended spacing, and some people require levothyroxine dose adjustments when they start iron supplementation.17PubMed Central. Levothyroxine Interactions with Food and Dietary Supplements–A Systematic Review – Section: Iron In one cohort study cited in that review, patients who used iron supplements were more than three times as likely to need repeated levothyroxine dose adjustments. Liquid levothyroxine formulations appear to be less susceptible to this binding problem, which is worth discussing with your doctor if the interaction keeps tripping you up.
The practical upshot for patients managing both Hashimoto’s and iron-deficiency anemia is straightforward but easy to get wrong. Take your levothyroxine first thing in the morning on an empty stomach, then wait at least four hours before taking iron. If your thyroid levels start creeping up despite stable levothyroxine doses, mention your iron supplement, because that interaction is one of the more common and underappreciated reasons for apparent levothyroxine “failure.”
Autoimmune Hemolytic Anemia and Hashimoto’s
Most anemia in Hashimoto’s patients falls into the categories already discussed: the bone marrow slowdown from low thyroid hormones, iron deficiency from poor absorption or blood loss, or B12 deficiency from co-occurring autoimmune gastritis. But there’s a rarer and more dramatic possibility that deserves mention. Autoimmune hemolytic anemia, in which the immune system directly attacks and destroys red blood cells, has been documented alongside Hashimoto’s thyroiditis as part of broader autoimmune polyendocrine syndromes. In these cases, the anemia isn’t caused by underproduction of red blood cells but by their accelerated destruction. The presentation is different: patients may develop jaundice, dark urine, and a rapid drop in hemoglobin that doesn’t respond to iron or B12. It’s uncommon, but the fact that it can occur alongside Hashimoto’s reinforces the broader principle that autoimmune conditions share underlying immune dysregulation, and anemia in a Hashimoto’s patient doesn’t always have a simple nutritional explanation.
If standard supplementation isn’t moving your blood counts, or if your lab work shows markers of red blood cell destruction rather than underproduction, the diagnostic workup needs to go beyond the usual thyroid-and-iron panel. A direct antiglobulin test can identify whether your immune system is targeting your own red blood cells, and catching autoimmune hemolysis early matters because the treatment, typically immunosuppression rather than supplementation, is completely different.